The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bellamy's unsubstantiated nonsense was removed.
Filter.
But the trouble is that would require 100% filtering and nobody replying which will never happen.
Replying is pointless and just prolongs the cycle of sealioning. đź¦đź¦đź¦
From not for.
You are correct, of course but I can tell you that without question you have invited a 200 word missive for the most relentless bore of them all.
Watch this space.....
“ Still nothing. It's beginning to look like a patient has dropped out.”
Not necessarily. Probably a DLT and therefore 3 more patients recruited.
Zero chance of finishing the 2 weekly by mid year as previously stated. Given themselves 6 months from 1st July to start the 1b. My guess be October onwards before that gets going.
There are individuals on the bb that produce constant negative comments that continually try to erode people’s belief on Avacta. They only shout out the negative facts whilst they muddy the waters on positive facts. They always an ulterior motive, be it they’re short or they’re looking for a low entry or even they’re been paid to disrupt this bb.
Wyndy and others have continually disrupted the board to the nth degree. It’s a real shame that we’ve lost so many good posters because of this disruption.
To those Individuals trying to disrupt this board, shame on you.
To those who are invested in Avacta, remember why you invested in the first place. Was it because of the science, management, or the fact that you could be investing in a company that could save millions of lives. Either way, it’s your decision.
The science works, there has been constant positive guidance on AV6000. We are seeing similar company’s (even at pre clinical) being bought for $bn’s. As Al said, our market cap should be around 300-450p.
Something will happen and the SP flip. Good luck to those with shorts or trying to buy in lower.
Patients are currently being dosed. SDMC were due to review C1 towards end of April, of course that is not within Avacta's gift to dictate, they hand over the results and they are reviewed. Hoping then for an update in the coming weeks.
Why does pointing out that there is a different interpretation (to the Pom Pom girls) to Al’s ambiguous communications count as Avacta bashing? Especially when the less positive interpretation has proved more correct nearly every time.
I don't see myself remotely as a victim? Thats your view not mine.
What I see is my poor judgement in holding a stock longer than I should have once it became obvious the RNS's were partial to the point of misleading.
That does not make me a victim. It just means its another bit of experience to take forward for the future.
The fact that many are so defensive here and take things, and want to make things, so personal is absurd when all we are discussing is a piece of paper (share certificate).
But the emotional investment many seem to have made is in my view counter productive to investment success and its a hard enough game as it is.
Spot on, Watching. Don't waste my time, Thornogson, or your own. Your history tells us all we need to know about you.
Other half of the tag team has arrived loool
PJT, I didn't realise that you'd met CC.
Was it for long and what did you talk about?
....."My only personal solace....." wouldn't be out of place if being uttered from Del Boy's lips :))))
Wyn, I've always supported your contrarian view in the past but even I find it hard to see you painting yourself as a "victim" here :))) I think your key sentence there is "My only personal solace is that I managed to profit from some trades". Rather gives the game away ;-)
I don’t believe you even own one share over the years you have only bashed this company
I wonder why !
Have you seen the trajectory of the SP over the last 3 years?
At what point should I start getting "excited" or positive?
I have stuck with this because I fell for the "Jam tomorrow" sentiment constantly argued by AS, believing that it really was just a few months away, and then just another few months, and then having waited this long, just another few months before the dfining data would be released/proved.
My only personal solace is that I managed to profit from some trades so it has not been the waste of time and money it has been for so many here.
But yes, I am about as disillusioned as I have been for many a year on what has been intimated by the BoD against what has been delivered.
It is shocking, absolutely shocking.
And the story has deteriorated, not improved over time. But at least I have had the sense to scale back my holding to reflect my perceived risk/reward.
I remember working for a very clever Cambridge educated graduate - who was a total idiot on the common sense / attention to detail fronts. Academic / scientific prowess isn't the only consideration in a CEO. I get the impression though that CC is very determined and doesn't suffer fools. Hopefully my judge of character is equally impressive!
You remember WAG, them sitting around for weeks waiting for the EU to approve the LFT only to be told on Twitter that the third party contracted to do it had forgotten to send their application in? Do you remember the Block Listing Six Monthly Return eleven days ago? Did you notice that the abstract for AACR 2024 said 51mg/m² not 54mg/m²? And many more examples. Hopefully the new regime will tighten up on this poor oversight. One can only hope that official submissions to the likes of the FDA don't have basic errors like these in them.
If an offer coming then $1-2bn at this point.
Here’s to the future ,whatever….
GLA
Wynbore All you have done for the last three years is had a ago about this company
Constantly being negative
Why would anyone do that if they owned shares
Why would anyone spend some much time here trying to suppress this bb
I quoted what he company said.
If the company does not keep the Share holders informed then it is further proof not to over commit.
If you are in some huge FTSE 100, where all that happens is the degree of profit alters from year to year then you can take a long term view.
AVCT is different. Its binary.
I mention this blindingly obvious fact only because it is not apparent to me on reading the majority of these posts.
Wynbore Only the company knows what’s. Going on ! Everything quoted on here is guess work so why waste your life churning verbal carp !
Based on this very favourable three-weekly dosing safety profile, Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.
The combined data from the three-weekly and two-weekly studies will provide information to allow the Company to define the dose and schedule to be used in future efficacy studies. Patients can be dosed in parallel in the two-weekly dose escalation study and Avacta remains on track to begin the dose expansion efficacy study in the second half of 2024. The data from the expansion study will be used to inform the optimal choice of a single orphan indication for the Phase 2 efficacy study which will follow on immediately.
Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:
"We are extremely pleased with the continued excellent progress of AVA6000 in the Phase 1a dose escalation study. These emerging data clearly demonstrate that the pre|CISION? peptide drug conjugate platform is functioning in the way it was designed and is capable of targeting the release of a cancer therapy to the tumor. Targeted therapy that spares healthy tissues is a holy grail of oncology drug development and we believe we have a unique platform to target FAP-rich tumor tissues to deliver significantly better outcomes for patients and substantial value to our shareholders.
"The continuing validation of the pre|CISION? platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION? to a range of warheads, including those much more potent than doxorubicin.
We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION? platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."
Lee Cranmer MD, PhD, FACP, Curtis and Elizabeth Anderson Endowed Professor in Sarcoma Research, University of Washington and Professor and Director of Sarcoma Oncology, Fred Hutchinson Cancer Center, commented:
"I am encouraged by the initial data with AVA6000 in the Phase 1 trial and look forward to working with my fellow investigators and our collaborators at Avacta to understand better the optimal dosing for this novel approach to targeted cancer therapy."
"Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA)."
That was sept......
Really, who knows whats going on....
You seem to be implying they have no procedures to follow, no peer review, no sign off. Ridiculous statement BV.